Microdosing means using doses below the 2.5 mg starter — often 1 mg or less weekly. There is no randomized trial evidence supporting it for weight management. It is used mainly for tolerability, cost control, or maintenance after reaching a goal.
Why people do it
Three reasons dominate: severe nausea at 2.5 mg, stretching an expensive vial across more weeks, and maintaining a result at the lowest effective exposure after reaching a target. The first and third are clinically reasonable conversations to have with a prescriber. The second is a cost problem masquerading as a dosing strategy.
What the evidence does and does not say
Every efficacy figure you have read — 20.9% at 15 mg, 15.0% at 5 mg — comes from trials of label doses. Nobody has run a randomized trial of 1 mg weekly for weight management. Anyone quoting a specific expected result from a microdose is extrapolating, not citing.
What is reasonable to infer: the dose–response curve is real, so less drug means less effect. Sub-2.5 mg dosing will produce less weight loss than the label doses in most people.
The accuracy problem
Measuring 0.5 mg from a compounded vial requires a very small volume and a syringe scaled for it. Dosing errors at these volumes are proportionally large. If you and your prescriber choose this route, get the volume in writing and use the syringe the pharmacy specifies.
Common questions
How much does tirzepatide cost per month without insurance?
Compounded tirzepatide from licensed US telehealth programs runs roughly $99 to $299 per month depending on the provider and whether the price is flat or scales with your dose. Brand-name Zepbound through LillyDirect self-pay runs about $299 to $449 per month depending on strength. Retail Zepbound without any program is around $1,089.
Is compounded tirzepatide the same as Zepbound?
The active ingredient is the same molecule. Zepbound is FDA-approved, manufactured by Eli Lilly and reviewed by FDA for safety, effectiveness and quality. Compounded tirzepatide is prepared by a state-licensed pharmacy for an individual patient and is not FDA-approved or FDA-reviewed. The pharmacology is identical; the quality assurance structure is not.
How much weight will I lose on tirzepatide?
In SURMOUNT-1, mean 72-week weight loss was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, versus 3.1% on placebo. If you have type 2 diabetes, expect roughly two-thirds of those figures based on SURMOUNT-2. Real-world averages run lower than trial averages, mostly because people stop early.
Is tirzepatide better than semaglutide?
For weight loss, yes, on the available randomized evidence. SURMOUNT-5 compared them head-to-head over 72 weeks and found 20.2% mean loss on tirzepatide versus 13.7% on semaglutide. Semaglutide retains a stronger cardiovascular outcomes label from the SELECT trial and is cheaper in compounded form.
People also ask about tirzepatide microdosing
What is tirzepatide microdosing?
Tirzepatide microdosing is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide microdosing apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide microdosing cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide microdosing FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.